FDAnews
www.fdanews.com/articles/181928-cma-accuses-merck-sharp-dohme-of-remicade-monopoly-pricing

CMA Accuses Merck Sharp & Dohme of Remicade Monopoly Pricing

May 25, 2017

The U.K.’s competition watchdog called out Merck Sharp & Dohme., alleging that the company has operated an anti-competitive discount scheme for Remicade, following an investigation launched in 2015. Remicade (infliximab) is used primarily in the treatment of Crohn’s disease, ulcerative colitis and rheumatoid arthritis.

The Competition and Markets Authority found that MSD broke competition law by abusing its dominant position through a discount scheme for Remicade that was likely to monopolize sales in the market against new biosimilar versions.

The findings are provisional, the CMA said, and no conclusion should be drawn that there has been any breach of competition law. The agency will consider any representations by the company before determining whether the law has been infringed.

View today's stories